Loading company…
Stemirna Therapeutics Co., Ltd. develops mRNA-based drugs for cancer, infectious diseases and genetic disorders.
Based in Shanghai, China, and established in 2016, Stemirna Therapeutics Co., Ltd. is led by founder and CEO Li Hangwen. It has partnerships with Baidu USA Research Institute, Oregon State University and the University of Rochester. Its June 2021 venture funding was intended for clinical trials and production of its COVID-19 vaccine candidate, and in May 2023 it raised an undisclosed amount of pre-series D funding. The company's vaccine production base covers 50,000 square meters, with capacity for 400 million doses as of 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in